Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Literature DB >> 30279227

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

François Lemonnier^1,2,3, Jehan Dupuis¹, Pierre Sujobert^4,5, Olivier Tournillhac⁶, Morgane Cheminant^7,8,9, Clémentine Sarkozy^5,10, Laura Pelletier³, Ambroise Marçais^7,8,9, Cyrielle Robe³, Virginie Fataccioli^3,11, Corinne Haioun^1,2,3, Olivier Hermine^7,8,9, Philippe Gaulard^2,3,11, Richard Delarue^7,8,9.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2018 PMID： 30279227 DOI： 10.1182/blood-2018-04-840538

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

41 in total

1. Interleukin-2-inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells.

Authors: Sami Mamand; Matthew Carr; Rebecca L Allchin; Matthew J Ahearne; Simon D Wagner
Journal: Blood Adv Date: 2019-03-12

2. TFH lymphomas: the times they aza-changin'?

Authors: David M Weinstock; Steven M Horwitz
Journal: Blood Date: 2019-10-24 Impact factor: 22.113

3. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort.

Authors: Johanne M Holst; Trine L Plesner; Martin B Pedersen; Henrik Frederiksen; Michael B Møller; Michael R Clausen; Marcus C Hansen; Stephen Jacques Hamilton-Dutoit; Peter Nørgaard; Preben Johansen; Tobias Ramm Eberlein; Bo K Mortensen; Gustav Mathiasen; Andreas Øvlisen; Rui Wang; Chao Wang; Weiwei Zhang; Hans Beier Ommen; Jesper Stentoft; Maja Ludvigsen; Wayne Tam; Wing C Chan; Giorgio Inghirami; Francesco d'Amore
Journal: Haematologica Date: 2019-11-28 Impact factor: 9.941

4. Emerging strategies in peripheral T-cell lymphoma.

Authors: Neha Mehta-Shah
Journal: Hematology Am Soc Hematol Educ Program Date: 2019-12-06

5. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Authors: François Lemonnier; Violaine Safar; Asma Beldi-Ferchiou; Anne-Ségolène Cottereau; Emmanuel Bachy; Guillaume Cartron; Virginie Fataccioli; Laura Pelletier; Cyrielle Robe; Audrey Letourneau; Edoardo Missiaglia; Slim Fourati; Marie-Pierre Moles-Moreau; Alain Delmer; Reda Bouabdallah; Laurent Voillat; Stéphanie Becker; Céline Bossard; Marie Parrens; Olivier Casasnovas; Victoria Cacheux; Caroline Régny; Vincent Camus; Marie-Hélène Delfau-Larue; Michel Meignan; Laurence de Leval; Philippe Gaulard; Corinne Haioun
Journal: Blood Adv Date: 2021-01-26

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

1. Interleukin-2-inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells.

2. TFH lymphomas: the times they aza-changin'?

3. Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort.

4. Emerging strategies in peripheral T-cell lymphoma.

5. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Review 6. Targeted based therapy in nodal T-cell lymphomas.

Review 7. Can we use epigenetics to prime chemoresistant lymphomas?

Review 8. Peripheral T cell lymphomas: from the bench to the clinic.

Review 9. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

10. Targeting epigenetic regulators in the treatment of T-cell lymphoma.